Profile data is unavailable for this security.
About the company
Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer and liver disease. The Company is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The Company's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The Company mainly conducts its businesses in China, the United States, Europe and South Korea.
- Revenue in HKD (TTM)0.00
- Net income in HKD-397.70m
- Incorporated2016
- Employees89.00
- LocationLaekna IncSHANGHAI 200120ChinaCHN
- Websitehttps://www.laekna.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hua Medicine | 82.61m | -227.78m | 1.67bn | 177.00 | -- | 14.20 | -- | 20.19 | -0.233 | -0.233 | 0.0846 | 0.1112 | 0.0538 | 1.69 | 13.03 | 466,720.80 | -14.84 | -25.61 | -17.56 | -28.81 | 48.78 | -- | -275.73 | -1,654.70 | 6.06 | -- | 0.6238 | -- | 335.31 | -- | -3.80 | -- | 14.07 | -- |
| Dawnrays Pharmaceutical (Holdings) Ltd | 1.24bn | 351.53m | 1.82bn | 1.14k | 5.17 | 0.5897 | 4.02 | 1.46 | 0.2339 | 0.2339 | 0.8261 | 2.05 | 0.3156 | 2.31 | 6.37 | 1,085,997.00 | 8.85 | 9.89 | 11.36 | 12.49 | 54.60 | 56.69 | 28.03 | 27.89 | 2.26 | 28.89 | 0.0405 | 35.33 | -9.90 | 3.94 | -8.95 | 1.41 | 63.92 | 2.00 |
| CStone Pharmaceuticals | 500.17m | -395.99m | 1.82bn | 230.00 | -- | 3.70 | -- | 3.65 | -0.3139 | -0.3139 | 0.396 | 0.3836 | 0.2811 | 2.44 | 3.72 | 2,174,639.00 | -22.25 | -54.76 | -48.85 | -81.68 | 65.60 | -- | -79.17 | -301.62 | 1.44 | -- | 0.4431 | -- | -3.64 | -- | 59.32 | -- | 52.42 | -- |
| SinoMab Bioscience Ltd | 1.47m | -262.15m | 2.02bn | 215.00 | -- | 6.01 | -- | 1,372.21 | -0.2575 | -0.2575 | 0.0015 | 0.308 | 0.0015 | -- | -- | 6,846.04 | -26.20 | -24.62 | -32.50 | -27.72 | 30.92 | -- | -17,810.33 | -4,451.74 | -- | -11.48 | 0.604 | -- | -- | -- | 14.45 | -- | 106.81 | -- |
| Acotec Scientific Holdings Ltd | 510.96m | 15.62m | 2.17bn | 638.00 | 133.39 | 1.55 | 33.16 | 4.25 | 0.052 | 0.052 | 1.70 | 4.46 | 0.3136 | 0.7213 | 3.44 | 800,872.40 | 0.9589 | -- | 1.03 | -- | 79.65 | -- | 3.06 | -- | 9.12 | 2.75 | 0.1529 | -- | 19.80 | -- | -79.35 | -- | -- | -- |
| Cutia Therapeutics | 148.40m | -2.12bn | 2.30bn | 298.00 | -- | 1.58 | -- | 15.52 | -6.97 | -6.97 | 0.4881 | 4.78 | -- | -- | -- | 497,988.90 | -- | -- | -- | -- | 51.60 | -- | -1,426.91 | -- | 5.38 | -- | 0.153 | -- | 1,110.83 | -- | -253.30 | -- | -- | -- |
| Abbisko Cayman Ltd | 20.55m | -465.38m | 2.42bn | 258.00 | -- | 1.13 | -- | 117.87 | -0.719 | -0.719 | 0.0318 | 3.04 | 0.0083 | -- | 1.40 | 79,661.44 | -18.74 | -- | -19.67 | -- | 100.00 | -- | -2,264.34 | -- | -- | -- | 0.0177 | -- | -- | -- | 12.92 | -- | -- | -- |
| Peijia Medical Ltd | 475.67m | -423.26m | 2.49bn | 1.04k | -- | 1.01 | -- | 5.23 | -0.6233 | -0.6233 | 0.7003 | 3.61 | 0.1473 | 0.7773 | 9.51 | 457,376.90 | -13.11 | -34.08 | -14.94 | -36.90 | 73.76 | 71.62 | -88.99 | -448.75 | 6.92 | -- | 0.0886 | -- | 75.86 | -- | 3.75 | -- | -- | -- |
| Frontage Holdings Corp | 2.03bn | 84.35m | 2.59bn | 1.76k | 31.11 | 0.9663 | 7.15 | 1.27 | 0.0408 | 0.0408 | 0.9799 | 1.31 | 0.463 | 60.63 | 5.32 | 1,152,935.00 | 1.91 | 4.46 | 2.33 | 5.28 | 30.17 | 34.00 | 4.13 | 9.92 | 1.39 | 4.09 | 0.296 | 0.00 | 3.79 | 25.61 | -58.00 | -0.7826 | 40.43 | -- |
| MicroPort CardioFlow Medtech Corp | 362.55m | -508.46m | 2.75bn | 592.00 | -- | 1.09 | -- | 7.59 | -0.2152 | -0.2152 | 0.1534 | 1.04 | 0.1205 | 2.78 | 3.67 | 612,407.30 | -16.91 | -17.37 | -18.11 | -22.96 | 2.06 | -1.67 | -140.25 | -180.82 | 9.91 | -11.56 | 0.0293 | -- | 33.94 | -- | -3.77 | -- | -14.16 | -- |
| Laekna Inc | 0.00 | -397.70m | 2.78bn | 89.00 | -- | 3.20 | -- | -- | -3.30 | -3.30 | 0.00 | 2.22 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -5.28 | 0.0655 | -- | -- | -- | 52.81 | -- | -- | -- |
| Golden Throat Holdings Group Co Ltd | 1.04bn | 269.75m | 2.80bn | 869.00 | 10.39 | 1.68 | 8.99 | 2.70 | 0.3649 | 0.3649 | 1.40 | 2.26 | 0.4181 | 4.82 | 1.85 | 1,192,941.00 | 10.88 | 11.00 | 15.85 | 15.63 | 72.57 | 72.79 | 26.02 | 24.67 | 2.48 | 34.74 | 0.21 | 83.15 | -3.09 | 6.73 | -11.04 | 19.61 | -32.13 | 38.94 |
| HighTide Therapeutics Inc | 0.00 | -1.01bn | 3.13bn | 66.00 | -- | 3.79 | -- | -- | -2.14 | -2.14 | 0.00 | 1.60 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0229 | -- | -- | -- | -393.76 | -- | -- | -- |
| China Isotope & Radiation Corp | 7.15bn | 400.02m | 3.60bn | 3.11k | 9.00 | 0.7117 | 3.33 | 0.5034 | 1.25 | 1.25 | 22.37 | 15.82 | 0.5312 | 4.22 | 1.84 | 2,304,219.00 | 6.21 | 6.57 | 12.82 | 13.26 | 52.48 | 59.89 | 11.70 | 12.62 | 1.73 | -- | 0.1919 | 28.27 | 7.82 | 15.35 | -5.43 | 2.88 | 3.63 | 2.92 |
| CARsgen Therapeutics Holdings Ltd | 0.00 | -806.36m | 3.70bn | 516.00 | -- | 1.91 | -- | -- | -1.45 | -1.45 | 0.00 | 3.38 | 0.00 | -- | -- | 0.00 | -29.79 | -- | -32.14 | -- | -- | -- | -- | -- | 9.54 | -- | 0.0452 | -- | -- | -- | 16.19 | -- | -- | -- |
| Biocytogen Pharmaceuticals Beijng Co Ltd | 773.06m | -412.94m | 3.89bn | 1.07k | -- | 4.59 | -- | 5.03 | -1.04 | -1.04 | 1.94 | 2.12 | 0.2732 | 16.21 | 5.74 | 725,193.00 | -14.59 | -- | -18.88 | -- | 70.59 | -- | -53.42 | -- | 1.24 | -21.30 | 0.4077 | -- | 34.28 | -- | 36.38 | -- | -- | -- |
Data as of May 23 2024. Currency figures normalised to Laekna Inc's reporting currency: Hong Kong Dollar HKD
0.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 1.39m | 0.36% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 161.50k | 0.04% |
| SSgA Funds Management, Inc.as of 09 May 2024 | 70.50k | 0.02% |
| China Asset Management (Hong Kong) Ltd.as of 31 Dec 2023 | 36.00k | 0.01% |
| Franklin Templeton Sealand Fund Management Co., Ltd.as of 31 Dec 2023 | 13.00k | 0.00% |
More ▼
Data from 31 Dec 2023 - 10 May 2024Source: FactSet Research Systems Inc.
